Jai Kumar Rajavoor Muniswamy

Dr. Jai Kumar Rajavoor Muniswamy


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2026 in Medicine
Verified
Journal Article
Open access
RHRaymond Haward
Raymond Haward
NDNikhil Duseja
Nikhil Duseja
HHHet Hirpara
Het Hirpara
HSHarkanwar Sandhu
Harkanwar Sandhu
SKSwathi Deepak Kulkarni
Swathi Deepak Kulkarni
JMJai Kumar Rajavoor Muniswamy
Jai Kumar Rajavoor Muniswamy
Portal hypertension is a central driver of morbidity and mortality in advanced chronic liver disease, yet its contribution to death is frequently underestimated owing to underreporting on death certificates. Population-level data on portal hypertension-related mortality trends and disparities in the United States remain limited. We conducted a retrospective, population-based mortality study using the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research Multiple Cause of Death database, identifying deaths with International Statistical Classification of Diseases and Related Health Problems, 10th Revision code K76.6 listed in any cause-of-death field from 1999 to 2023. Crude and age-adjusted mortality rates per 100,000 population were calculated and stratified by sex, U.S. Census region, race/ethnicity, and urban–rural status (the latter restricted to 1999–2020 due to data availability). Temporal trends were assessed using Joinpoint regression, with annual percent change (APC) reported as the primary trend metric and 95% confidence intervals presented for all estimates. A total of 34,551 portal hypertension-related deaths were identified. Overall age-adjusted mortality rates declined sharply from 1999 to 2002 (APC − 12.85%), plateaued for more than a decade, and rose thereafter. Mortality increased significantly in women after 2009 (APC + 6.69%) and in men after 2013 (APC + 6.18%). Among racial and ethnic groups, Hispanic or Latino individuals consistently demonstrated the highest mortality burden throughout the study period, followed by White individuals, whereas Black or African American individuals exhibited comparatively lower but significantly rising rates from 2006 onward. White individuals demonstrated the steepest recent acceleration, with a significant increase after 2014 (APC + 8.51%). Regionally, the South experienced the steepest post-2013 increase, while the Northeast retained the lowest absolute rates despite a significant rise after 2014. Urban populations showed early improvement through 2014 followed by rising mortality, whereas rural populations experienced a later but steeper rise beginning around 2013, with widening urban–rural disparities over time. Portal hypertension-related mortality has risen significantly since the mid-2010s across all demographic and geographic subgroups, with disproportionate burdens among Hispanic individuals, men, rural populations, and residents of the Southern United States. These findings highlight the urgent need for targeted prevention strategies, equitable access to hepatology care, and aggressive management of metabolic and alcohol-related risk factors to reverse this trajectory.

18 September 2026 in Medicine
Verified
Journal Article
Open access
RHRaymond Haward
Raymond Haward
NDNikhil Duseja
Nikhil Duseja
HSHarkanwar Sandhu
Harkanwar Sandhu
SBShankar Biswas
Shankar Biswas
JMJai Kumar Rajavoor Muniswamy
Jai Kumar Rajavoor Muniswamy
SKSwathi Deepak Kulkarni
Swathi Deepak Kulkarni
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and α-synuclein aggregation, resulting in motor dysfunction and increasing mortality. Chronic kidney disease (CKD), affecting nearly 700 million people worldwide, is associated with systemic inflammation, vascular dysfunction, and excess mortality. Emerging evidence suggests a bidirectional relationship between CKD and PD, with renal impairment potentially accelerating neurodegeneration and worsening clinical outcomes. This study examined national mortality trends among individuals with coexisting PD and CKD in the United States from 1999 to 2023. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Mortality data were obtained from the CDC WONDER database. Deaths listing both PD (International Classification of Diseases, Tenth Revision [ICD-10]: G20) and CKD (ICD-10: N18) were identified. Age-adjusted mortality rates (AAMRs) per 1,00,000 population were standardized to the 2000 US population and stratified by year, sex, region, and urban-rural status. Joinpoint regression estimated Annual percent change (APC), with P < .05 considered statistically significant. Between 1999 and 2023, 20,437 deaths were attributed to coexisting PD and CKD. National AAMR increased more than 4-fold, from 0.1 to 0.5 per 1,00,000 (APC = 5.23; 95% CI: 3.92–6.55). Mortality increased in females (0.1–0.3; APC = 5.15; 95% CI: 3.35–6.99) and males (0.2–0.8; APC = 4.79; 95% CI: 3.57–6.02). All census regions demonstrated significant increases, with the greatest rise in the West (APC = 5.92; 95% CI: 4.22–7.64). Mortality also increased in both urban (APC = 5.01) and rural (APC = 4.78) populations. Mortality among individuals with coexisting PD and CKD has risen substantially across demographic and geographic groups in the United States over the past 2 decades. These findings highlight the need for integrated neurology-nephrology care, early recognition of renal dysfunction, and targeted risk-factor management. Further research is warranted to clarify underlying mechanisms and develop strategies to reduce mortality in this high-risk population.